CSL Ltd (CSL.AX) Key Developments | Reuters.com
Edition:
United States

CSL Ltd (CSL.AX)

CSL.AX on Australia Stock Exchange

108.36AUD
29 Jun 2016
Change (% chg)

-- (--)
Prev Close
$108.36
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,066,750
52-wk High
$117.61
52-wk Low
$85.40

Latest Key Developments (Source: Significant Developments)

CSL says US food and drug administration approved AFSTYLA
Wednesday, 25 May 2016 07:19pm EDT 

CSL Ltd : US food and drug administration (FDA) has approved AFSTYLA .Says afstyla is expected to be available in the US early this US summer.  Full Article

CSL announces FDA approval of its influenza vaccine
Monday, 23 May 2016 06:48pm EDT 

CSL Ltd : Flucelvax quadrivalent (influenza vaccine) - FDA approval . US food and drug administration (FDA) has approved seqirus' flucelvax quadrivalenttm .  Full Article

CSL Ltd Names David Lamont CFO
Thursday, 8 Oct 2015 06:07pm EDT 

CSL Ltd:Names David Lamont CFO effective 2 January 2016.  Full Article

CSL Limited closed a new 400 million swiss franc and $100 million private placement
Thursday, 8 Oct 2015 06:05pm EDT 

CSL Limited:Says that on 8 October 2015 it has closed a new 400 million swiss franc and $100 million private placement in the US.Says private placement was foreshadowed in CSL's full year results announcement in August 2015.  Full Article

CSL Ltd announces issue of ordinary shares
Tuesday, 23 Jun 2015 12:55am EDT 

CSL Ltd:Issues 2,395 ordinary shares.  Full Article

CSL Ltd issues ordinary shares
Tuesday, 10 Mar 2015 12:15am EDT 

CSL Ltd:Issues 146,475 fully paid ordinary shares.  Full Article

CSL Ltd gives FY 2015 sales outlook-Conference Call
Tuesday, 10 Feb 2015 07:00pm EST 

CSL Ltd:Expect FY 2015 sales to grow organically in the mid to high single-digits, that doesn't include the potential contribution from LHI or Fluid Technologies.Reported revenue of $5.781 billion in FY 2014.  Full Article

CSL Ltd launches AEGIS-I, a phase 2b clinical study of CSL112, a Apolipoprotein A-I Infusion Therapy Designed to Rapidly Remove Cholesterol from Arteries and Stabilize Plaque
Wednesday, 12 Nov 2014 08:00am EST 

CSL Ltd:Announced the launch of AEGIS-I, a Phase 2b clinical study of CSL112, a formulation of apolipoprotein A-I (apoA-I).Administered as a short series of weekly infusions, CSL112 is designed to rapidly remove cholesterol from the arteries and stabilize lesions at risk of rupture.Says this represents a new approach to reduce the high incidence of early recurrent cardiovascular events in the days and weeks following a heart attack.AEGIS-I is a Phase 2b, global, randomized, placebo-controlled, dose-ranging study investigating the safety and tolerability of multiple dose administration of CSL112 in 1,200 patients who experienced an acute myocardial infarction or heart attack.AEGIS-I is a Phase 2b, global, randomized, placebo-controlled, dose-ranging study investigating the safety and tolerability of multiple dose administration of CSL112 in 1,200 patients who experienced an acute myocardial infarction or heart attack.Results of the study are expected in 2016.  Full Article

CSL Limited to acquire Novartis influenza vaccine business
Sunday, 26 Oct 2014 05:37pm EDT 

CSL Limited:Says that it has agreed to acquire Novartis’ global influenza vaccine business for $275 million.Says the business will be combined with CSL’s subsidiary, bioCSL.Says the final settlement of the transaction is expected to occur in the second half of calendar year 2015.Says the acquisition is expected to be funded through surplus cash.  Full Article

Novartis AG announces divestiture of influenza vaccines business to CSL Ltd for $275 million
Sunday, 26 Oct 2014 05:01pm EDT 

Novartis AG:Enters into definitive agreement to divest its influenza vaccines business to CSL Ltd for agreed price of $275 million.Says this transaction requires regulatory approvals and is expected to close in second half of 2015.Novartis influenza vaccines unit will be combined with CSL's subsidiary, bioCSL.  Full Article